Association Between Genetic Variant Scores and DOACs (DARES2)
NCT04597593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2023-08-16
Summary
The study's objective is to evaluate the predictive accuracy of Cipherome's algorithm in predicting and preventing serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).
Conditions
- Drug-Related Side Effects and Adverse Reactions
- Iatrogenic Disorder
Sponsors & Collaborators
-
Seoul National University Bundang Hospital
collaborator OTHER -
Cipherome, Inc.
lead INDUSTRY
Principal Investigators
-
Ilyoung Oh, MD · SNUBH
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-07
- Primary Completion
- 2022-12-29
- Completion
- 2022-12-30
Countries
- South Korea
Study Locations
More Related Trials
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
NCT05750680 ·Status: ACTIVE_NOT_RECRUITING
-
Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography
NCT02448901 ·Status: UNKNOWN
-
Pharmacogenetics of Acenocoumarol
NCT01492777 ·Status: COMPLETED
-
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
NCT04565977 ·Status: COMPLETED
-
Clinical and Economic Implications of Genetic Testing for Warfarin Management
NCT00964353 ·Status: COMPLETED ·Phase: PHASE4
-
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
NCT02841085 ·Status: COMPLETED
-
LEAVE Safe With DOACs
NCT04068727 ·Status: COMPLETED ·Phase: NA
-
Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
NCT03180567 ·Status: UNKNOWN ·Phase: NA
-
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
NCT05022563 ·Status: COMPLETED
-
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
NCT02720328 ·Status: COMPLETED ·Phase: PHASE4
-
Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing
NCT00484640 ·Status: UNKNOWN ·Phase: NA
-
Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
NCT00511173 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
NCT00806624 ·Status: COMPLETED ·Phase: PHASE2
-
Clarification of Optimal Anticoagulation Through Genetics
NCT00839657 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants
NCT06582563 ·Status: NOT_YET_RECRUITING
-
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01119300 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN
-
Genetic Response to Warfarin in Healthy Subjects
NCT01520402 ·Status: COMPLETED ·Phase: NA
-
DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
NCT03112525 ·Status: COMPLETED
-
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
NCT06692504 ·Status: RECRUITING
-
Pharmacogenetics of Warfarin Induction and Inhibition
NCT01447511 ·Status: COMPLETED ·Phase: NA
-
Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers
NCT02171559 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective Cohort Study on Warfarin Personalized Medication
NCT06428110 ·Status: COMPLETED